Physician profile
Lea Nickolas
NPI 1306471644
$7,045.77
in general payments reported to CMS, 2019-2025
21 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $2,096 · 2023: $2,325 · 2024: $1,605 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,322.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,812.57 | 2021-2025 | Descovy, Biktarvy |
| Viiv Healthcare Company | $2,307.23 | 2021-2025 | Cabenuva, Rukobia, Apretude |
| Janssen Biotech, INC. | $424.85 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $403.03 | 2022-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $307.49 | 2023-2024 | |
| Janssen Products, Lp | $177.53 | 2022-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $127.48 | 2024 | Spravato |
| Organon LLC | $86.72 | 2022 | |
| Napo Pharmaceuticals INC | $71.31 | 2024-2025 | Mytesi |
| Astrazeneca Pharmaceuticals Lp | $47.06 | 2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.20 | 2024 | Jardiance |
| Novo Nordisk INC | $42.02 | 2024-2025 | Ozempic, Rybelsus |
| Indivior INC. | $29.94 | 2024 | Sublocade |
| Theratechnologies INC. | $28.86 | 2021 | |
| Angiodynamics, INC. | $22.74 | 2023 | Auryon Laser System 100-120 Vac |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $20.45 | 2024 | |
| Lilly USA, LLC | $20.07 | 2024 | Zepbound, Mounjaro |
| Amgen INC. | $19.94 | 2024 | Repatha, Otezla |
| Emd Serono, INC. | $19.83 | 2023 | Serostim |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.40 | 2024 | Lifevest |
| Oxford Immunotec USA INC | $15.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Nickolas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.